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BMP = bone morphogenetic protein; CDMP-1 = cartilage-derived morphogenetic protein-1.
Available online http://arthritis-research.com/content/3/1/001
Introduction
The sequelae of damage and degradation of articular carti-
lage is well known in osteoarthritis. Repair and regeneration
of articular cartilage in experimental animals is initiated when
the subchondral bone is penetrated, as in full thickness
defects. On the other hand, there is no repair in partial thick-
ness defects with the defect confined to cartilage only. Sub-
chondral bone with associated matrix and hematopoietic
stromal cells may thus play a role in cartilage repair. The dif-
ference in regenerative potential between bone and carti-
lage is immense. The fundamental differences between
cartilage and bone in inherent repair potential may be due to
differences in concentration of endogeneous growth and
morphogenetic factors and their antagonists. The deminer-
alized bone matrix is a repository of BMPs and this might
explain, in part, the repair of articular cartilage in full thick-
ness defects. The aim of this commentary is to discuss the
interplay between the evolving family of BMPs and cognate
BMP binding proteins in bone and cartilage development. In
arthritis, with attendant cartilage damage, there is a
derangement of the morphogenetic signals. It is thus possi-
ble to harness the recent progress in developmental biology
of morphogens to design rational therapeutic approaches to
cartilage regeneration. Regeneration is, after all, a recapitu-
lation of embryonic development and morphogenesis, and
includes redeployment of morphogens in regeneration.
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Abstract
This commentary is a concise discussion of the interactions between bone morphogenetic proteins
(BMPs) and their binding proteins in bone and cartilage morphogenesis. BMPs are a family of growth
and differentiation factors, and they act on mesenchymal cells to induce cartilage and bone
differentiation in concentration-dependent thresholds. The BMP–BMP receptor binding leads to a
cascade of signaling and transcription of BMP response genes. BMP binding proteins, noggin, chordin
and DAN, act as antagonists and determine the bioavailability of BMPs for binding to cognate
receptors to elicit the biological response. Noggin null mice with unrestricted action of BMPs exhibit
defects in joint morphogenesis. BMPs and their binding proteins may reciprocally regulate the dynamic
topography of joints, muscle, tendons and ligaments during morphogenesis of the skeleton. In addition,
BMP actions may be potentiated by twisted gastrulation. BMPs and their binding proteins may play a
critical role in regeneration of cartilage in osteoarthritis.
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Bone morphogenetic proteins
BMPs are a family of growth and differentiation factors
[1,2]. BMPs are pleiotropic morphogens, and they induce
new cartilage and bone formation in ectopic sites by a
developmental sequence that mimics limb development
and morphogenesis. BMPs have chemotactic, mitogenic
and differentiation-inducing properties. The actions of
BMPs are concentration dependent, and are based on
thresholds. BMPs are dimeric proteins with a single inter-
chain disulfide bond. The dimeric conformation is an
absolute requirement for the biological action and interac-
tion with receptors.
BMPs were initially identified as bioactive molecules in the
demineralized bone matrix responsible for cartilage and
bone differentiation [1,2]. BMPs regulate the lineage,
pattern and differentiation of bone, and over 15 have been
cloned and expressed in humans and mice. Genetic evi-
dence points to actions of BMPs in tissues beyond bone.
Knockout of BMP 2 and BMP 4 results in defects in meso-
derm formation. Mutations in BMP 5 in mice are responsi-
ble for the short ear phenotype. BMP 7 null mice exhibit
defects in eye, kidney and skeleton [2]. BMP 4 stimulates
chondrogenesis in limb bud mesenchymal cells [3] and
maintains articular cartilage phenotype [4].
Cartilage-derived morphogenetic proteins
Luyten and coworkers identified cartilage-derived morpho-
genetic protein-1 (CDMP-1) in articular cartilage [5] and
found it identical to growth/differentiation factor 5. The
incisive work of Lee and coworkers cloned growth/differ-
entiation factors 5, 6, and 7, with mutations in growth/dif-
ferentiation factor 5 identified in mouse brachypodism [6].
It is noteworthy that mutations in human CDMP-1 were
identified in patients with Hunter–Thompson type chon-
drodysplasia, type C Brachydactyly and Grebe type chon-
drodysplasia with severe limb shortening and impaired
morphogenesis [7,8]. BMPs and CDMPs are thus critical
for bone and cartilage morphogenesis and beyond. BMPs
should perhaps be called body morphogenetic proteins,
which would take into account the wide-ranging actions of
BMPs and obviate the need for tinkering with terminology.
BMP receptors
There are seven canonical conserved cysteines in the
mature monomer, six of which are involved in intrachain
disulfide bonds. The seventh is key for the interchain disul-
fide bond. The BMP monomer forms two finger-like projec-
tions from the palm of the hand. BMPs interact with
specific receptors. Recombinant human BMP 4 and
BMP 7 bind to two distinct type I BMP receptors, BMPR-IA
and BMPR-IB, and BMP 7 also appears to bind to activin-
type I receptor. BMPs also bind to type II BMP receptors,
with both BMP receptors I and II being serine/threonine
kinases. A gene from Caenorhabditis elegans, daf 4, binds
to recombinant human BMP4. Expression of daf 4 inhibits
dauer larva formation. Three genes, Sma 2, Sma 3 and
Sma 4, were identified in daf 4 signaling in C. elegans. Sys-
tematic genetic screens in Drosophila melanogaster identi-
fied a gene mother against decapentaplegic (Mad). There
was sequence homology between Sma 2, Sma 3, and
Sma 4 in  C. elegans and  Mad in  Drosophila, and the scien-
tists have fused the terms Sma and Mad to Smad in
mammals. There are three classes of Smads. The receptor-
regulated R-Smad 1, R-Smad 5 and R-Smad 8 are phos-
phorylated by BMP receptor kinases [9]. X-Ray
crystallography has revealed the trimeric nature of Smads.
The R-Smads interact with a common signaling partner
Co-Smad, Smad 4. The multimeric protein complex of
Smad 1/5/8 and Smad 4 is translocated into the nucleus
and initiates transcription of BMP response genes. The
type I receptor kinase catalyzed phosphorylation of Smad 1
and Smad 5 is inhibited by inhibitory Smads, Smad 6 and
Smad 7. These inhibitory Smads are normally resident in
the nucleus, act as a homeostatic relay upon BMP stimula-
tion of cells and are translocated into the cytosol to inhibit
type I BMP receptor kinase catalyzed phosphorylation of
Smad 1/5. This intricate signaling is dependent on the
bioavailability of BMPs at steady state to the cognate
receptors. BMP levels and interaction with receptors is
dependent on binding to the extracellular matrix and BMP
binding proteins (Fig. 1). BMPs bind to extracellular matrix
components and thus the availability of BMP for receptor
binding is restricted [10]. The extracellular matrix may
potentiate the biological actions of BMPs [10].
BMP binding proteins as antagonists
Noggin
During the course of a search for the elusive neural
inducer, noggin was isolated from Xenopus based on
rescue of dorsal development in ultraviolet-induced ven-
tralized embryos [11]. Injection of the putative cloned RNA
into embryos resulted in large heads, hence the name
noggin. Noggin is produced by the Spemann organizer
and antagonizes the action of BMPs, induces neural tissue
and dorsalizes ventral mesoderm. Noggin binds to BMP 2
and BMP 4 with high affinity and blocks interaction with
BMP receptor [12]. The bioavailability receptor is thus
modulated by BMP antagonist noggin.
What has noggin to do with arthritis and articular cartilage?
The precise boundary between muscle and cartilage with
the interspersed perichondrium, the tendon/ligament inter-
face, requires precisely regulated boundary conditions
during joint morphogenesis. One can envisage, given the
role of dominant morphogens such as BMPs and CDMPs,
BMP/CDMP binding proteins (antagonists) to play a role in
defining boundaries. Experimental evidence has in fact
been adduced to precisely demonstrate this, using noggin
null mice generated by homologous recombination [13].
Regulated cell death and joint cavitation follow mesen-
chymal cell condensation in regions of presumptive jointc
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morphogenesis, and CDMP-1 has been implicated in this
process [13]. It is possible in mice lacking noggin that the
unfettered actions of BMPs/CDMPs may lead to impaired
joint formation. Defects in vertebrae, ribs and limbs were
observed in homozygous mutants; heterozygous mice
appeared normal. The limbs are shorter in the mutant, the
joints were not demarcated and fusion of the joints was
commonplace. Optimal expression of BMPs/CDMP is thus
needed for the normal joint morphogenesis. Future investi-
gations with conditional knockouts of noggin in mice will
shed more light on the role of noggin in joint morphogene-
sis. BMP 2 induces the expression of noggin in osteoblasts
[14] and bone marrow cells [15], implying regulated
expression of the BMP antagonist, perhaps to downregu-
late the agonist response to BMP 2. This is akin to a molec-
ular thermostat to maintain skeletal homeostasis.
Chordin
During the course of investigation on Xenopus pattern for-
mation, chordin was identified as BMP 4 binding protein
[16]. Chordin has a homolog in Drosophila, short gastrula-
tion (sog), known to bind to decapentaplegic, a BMP 2/4
homolog. These BMP antagonists have thus been con-
served for several million years. Chordin binds to BMP 2
Available online http://arthritis-research.com/content/3/1/001
Figure 1
BMP receptors and signaling cascades. BMPs are dimeric ligands with a cysteine knot in each monomer fold. Each monomer has two b sheets
(represented as two pointing fingers). These fingers in the functional dimer are oriented in opposite directions. BMPs interact with both type I and
type II BMP receptors (BMPR-I and BMPR-II). The exact stoichiometry of the receptor complex is currently being elucidated. BMPR-II
phosphorylates the glycine–serine (GS) domain of BMPR-I. The collaboration between type I and type II receptors forms the signal transducing
complex. The BMP type I receptor kinase complex phosphorylates the trimeric signaling substrate Smad 1 or Smad 5. This phosphorylation is
inhibited and modulated by inhibitory Smad 6 and Smad 7. Phosphorylated Smad 1 or Smad 5 interacts with Smad 4 (functional partner) and
enters the nucleus to activate the transcriptional machinery for early BMP response genes. A novel Smad interacting protein may interact and
modulate the binding of heteromeric Smad 1/Smad 4 complexes to the DNA. The bioavailability of BMP for interaction with BMP receptors is
determined by binding to extracellular matrix components such as heparan sulfate and collagen IV. The BMP antagonists noggin, chordin and DAN
can also bind with high affinity to BMP and prevent interaction with receptors. There is thus a very intricate regulation of BMP biological actions.and BMP 4, and is further regulated by a metalloprotease
BMP 1 and tolloid and Xenopus xolloid [17–19]. Antago-
nists such as chordin thus govern the intricate pattern for-
mation by morphogens such as BMP, and in turn are
proteolytically inactivated by a metalloprotease BMP 1,
related to the astacin family. BMP 1 was originally identi-
fied in osteogenic extracts derived from bovine bone as it
copurified with bonafide bone morphogenetic proteins
2–7 [1]. BMP 1 also functions as a procollagen c-pro-
tease. In retrospect, the term BMP-1 is a misnomer, as this
BMP does not induce bone morphogenesis.
DAN
The DAN gene was isolated as a candidate tumor sup-
pressor gene in a differential hybridization screen [20].
Secreted DAN suppressed DNA synthesis in transformed
cells. The head inducer gene Cereberus codes for a
secreted protein and can induce heads in Xenopus
embryos, and it is related to DAN in the cysteine rich
domain [21]. Gremlin is a Xenopus homolog related to
DAN that inhibits BMP 2 action and was identified by
screening an ovarian cDNA library for activities inducing
the secondary axis [22]. DAN family members are thus
newly identified BMP antagonists [23–25]. It is not yet
clear if they play a role in articular cartilage and in arthritis.
BMP potentiating agonist: twisted
gastrulation
One of the emerging themes in developmental biology is
the regulation of pattern formation and morphogenesis by
sets of genes. The anterior–posterior axis, for example, is
governed by hox genes. The dorsal–ventral axis is the
result of the activity and expression pattern of bone mor-
phogenetic proteins, BMP antagonist chordin and metallo-
protease xolloid. Recent work in Xenopus has identified a
gene ‘twisted gastrulation’ (xTsg), as an agonist of BMP
actions [26]. In vertebrates, the dorsal–ventral pattern is
regulated by a gradient of BMP activity. Although BMPs
are expressed uniformly, the expression of BMP antago-
nists such as chordin generates the dorsal–ventral gradi-
ents. Further control is exerted by xolloid, a zinc-dependent
metalloprotease. The xTsg binds to BMPs with a dissocia-
tion constant in the low nanomolar range. It is noteworthy
that microinjection of xTsg results in potentiation of BMP
signaling, leading to ventralization of Xenopus embryo.
Twisted gastrulation is thus an agonist of BMP signaling.
xTsg may thus activate the inactive BMP–chordin cysteine
rich domain complex by releasing the bioactive BMPs. It is
important to bear in mind, given BMPs bind to extracellular
matrix [10,27] components such as collagens, heparan
sulfate and heparin, additional regulation is inevitable, and
is a question of time and space!
Conclusion
The recent advances in the developmental biology of BMP
binding proteins will allow a rational approach to the chal-
lenges of articular cartilage repair by morphogens. It is
remarkable how Nature zealously regulates the intricate
interplay between BMPs, BMP receptors, extracellular
matrix, BMP antagonists such as noggin, chordin and the
DAN family, and BMP potentiating twisted gastrulation.
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